Edaglitazone是一种高效选择性口服活性PPARγ激动剂，其对PPARγ和PPARα的EC50值分别为35.6 nM和1053 nM，具有显著的抗血小板聚集、抗糖尿病及降血糖活性，在代谢性疾病治疗研究中具有应用潜力。
/
-25~-15℃避光保存，有效期3年。
[1] Muñoz-Gutiérrez C, Sepúlveda C, Caballero J, Palomo I, Fuentes E. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci. 2017 Oct 1;186:59-65. doi: 10.1016/j.lfs.2017.07.031. Epub 2017 Jul 28. PMID: 28757415. [2] Fürnsinn C, Brunmair B, Meyer M, Neschen S, Furtmüller R, Roden M, Kühnle HF, Nowotny P, Schneider B, Waldhäusl W. Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br J Pharmacol. 1999 Nov;128(6):1141-8. doi: 10.1038/sj.bjp.0702886. PMID: 10578125; PMCID: PMC1571739.
